In the Cox regression analysis of the AML cohort, no statistically significant association was identified between overall survival and age, risk category, or biomarker levels (HIF-1α, eIF2AK3, GRP78, ATF6, CHOP, and caspase 3).<h4>Conclusion</h4>PERK and ATF6 signaling pathways were activated in patients with AML. The gene discussed is EIF2AK3; the disease is acute myeloid leukemia.